CPG 7909 Injection in Melanoma

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Dacarbazine

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed melanoma that is metastatic.

• Measurable disease according to the RECIST criteria.

• Karnofsky Performance Status of > 70.

Exclusion Criteria:

• Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or metastatic disease (except one course of adjuvant immunotherapy and/or adjuvant chemotherapy other than DTIC).

• Suspected or known CNS metastases.